West Pharmaceutical (NYSE: WST) CEO Eric Green to retire in 2026

Rhea-AI Filing Summary

West Pharmaceutical Services, Inc. announced that Eric M. Green, its President, Chief Executive Officer and Chair of the Board, plans to retire from all three roles once a successor is hired to support a smooth leadership transition.

The Board has engaged a leading executive recruiting firm and expects the transition to occur in the second half of 2026. At the same time, the Company reaffirmed its previously issued 2026 financial guidance from its February 12, 2026 earnings release.

Green has led West as President and CEO since April 2015 and became Chair in May 2022. During his tenure, the Company more than doubled sales, achieved total shareholder return of approximately 350%, and generated $3.07 billion in net sales in fiscal 2025.

Insights

Corporate governance and leadership transition analyst

Planned CEO/Chair retirement with clear search process and reaffirmed 2026 guidance.

West Pharmaceutical Services disclosed that long-tenured leader Eric M. Green will retire as President, CEO and Chair once a successor is appointed. The Board is using an external executive search firm and targets completing the transition in the second half of 2026, signaling a structured, non-abrupt change.

The Company simultaneously reaffirmed its 2026 financial guidance from the February 12, 2026 earnings release, suggesting no immediate change to near-term financial expectations tied to this announcement. Leadership highlighted that under Green, sales more than doubled and total shareholder return reached about 350%, with net sales of $3.07 billion in fiscal 2025.

For investors, the key variables will be the identity and track record of the eventual successor and any updates to strategic priorities once that person is in place. Subsequent company communications after the leadership handoff may clarify continuity of strategy and long-term growth ambitions.

0000105770false00001057702026-03-092026-03-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – March 9, 2026

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

1-8036

23-1210010

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

530 Herman O. West Drive, Exton, PA

19341-1147

(Address of principal executive offices)

(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, par value $0.25 per share			WST			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Today, March 9, 2026, West Pharmaceutical Services, Inc. (the “Company”) announced that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026.

Item 7.01 Regulation FD Disclosure.

A copy of the press release regarding this announcement of Mr. Green’s intent to retire from the Company and the Board and the Company’s reaffirmation of its 2026 financial guidance provided in its February 12, 2026 earnings release is furnished as Exhibit 99.1 to this report and is incorporated into this Item 7.01 by reference thereto.

The information in this Item 7.01 of this Current Report on Form 8-K, including the exhibit furnished pursuant to Item 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that Section. Furthermore, the information in this Item 7.01 of this Current Report on Form 8-K, including the exhibit furnished pursuant to Item 99.1, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)			Exhibit No.			Description
			99.1			West Pharmaceutical Services, Inc. Press Release, dated March 9, 2026 (furnished, not filed).
			104			The cover page from the Company’s Current Report on Form 8-K, dated March 9, 2026, formatted in Inline XBRL.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 9, 2026			WEST PHARMACEUTICAL SERVICES, INC.
By:			/s/ Norman D. Finch Jr.
			Norman D. Finch Jr.
			Senior Vice President, General Counsel and Corporate Secretary

3

EXHIBIT INDEX

Exhibit No.						Description
99.1						West Pharmaceutical Services, Inc. Press Release, dated March 9, 2026 (furnished, not filed).
104						The cover page from the Company’s Current Report on Form 8-K, dated March 9, 2026, formatted in Inline XBRL.

4

Investor Contact: Media Contact: John Sweeney, CFA Michele Polinsky Vice President, Investor Relations Vice President, Global Communications +1-484-790-0373 +1-610-594-3054 John.Sweeney@westpharma.com Michele.Polinsky@westpharma.com    Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc. EXTON, Pa., March 9, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. In parallel with today’s announcement, the Company is reaffirming the guidance set forth in its February 12, 2026 press release. "After serving 11 years as the Company’s 6th CEO over the past century, it is time for someone else to take over the leadership of West," Green said. "I have great confidence in the strong leadership team we have in place to carry on with the current momentum to take this extraordinary Company forward. I am especially thankful to the Board of Directors for giving me this stewardship to lead West over more than a decade and for their support of my decision. My decision provides the opportunity to serve in the future in other capacities, including corporate boards and advisory roles." "We are grateful to Eric for his remarkable service to West," said Robert F. Friel, Lead Independent Director of the Board of Directors. "His eleven-year tenure is marked by exceptional revenue and enterprise value growth, having more than doubled the sales of the Company during that time and achieved total shareholder return of approximately 350%." "In addition to these accomplishments, during Eric’s tenure the Company drove innovations that uniquely meet patients’ needs, responded to the unprecedented COVID pandemic by supporting the delivery of vaccines around the world, and significantly grew our global impact." "As the leading provider of innovative, high-quality injectable solutions and services, the Company is in an excellent position to achieve its long-term growth ambitions and to continue to create value for patients, customers and shareholders," Green added.

Green has served as President and Chief Executive Officer of West since April 2015, and he became Chair of the Board in May 2022. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company’s expectations regarding future events, financial guidance and financial or operational performance. Forward-looking statements may be identified by words such as “believe,” “expect,” “intend,” “estimate,” “plan,” “anticipate,” “project,” “forecast,” “guidance,” “target,” “may,” “will,” “continue” and similar expressions. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For additional information regarding these risks as well as other risks, uncertainties and factors that could affect our forward-looking statements, please refer to Part I Item 1A, entitled "Risk Factors," of the Company's most recent Annual Report on Form 10-K and any amendments thereto, as well as the Company’s most recently filed Quarterly Reports on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release. Except as required by law or regulation, West Pharmaceutical Services, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

What leadership change did West Pharmaceutical Services (WST) announce?

West Pharmaceutical Services announced that Eric M. Green plans to retire as President, CEO and Chair of the Board once a successor is hired, with the Board expecting the leadership transition to occur in the second half of 2026.

When is West Pharmaceutical (WST) expecting the CEO transition to take place?

The Company expects the leadership transition to occur in the second half of 2026. The Board is engaging a leading executive recruiting firm to identify and hire a successor before Eric M. Green retires from his roles.

Did West Pharmaceutical Services (WST) change its 2026 financial guidance?

West Pharmaceutical reaffirmed the 2026 financial guidance it provided in its February 12, 2026 earnings release. The guidance confirmation accompanied the CEO retirement announcement, indicating no stated adjustment to previously communicated outlook figures.

How has West Pharmaceutical (WST) performed under CEO Eric M. Green?

During Eric M. Green’s roughly eleven-year tenure, West more than doubled its sales and delivered total shareholder return of approximately 350%. In fiscal year 2025, the Company generated $3.07 billion in net sales, reflecting substantial growth over his period of leadership.

What does West Pharmaceutical Services (WST) do and how large is it?

West Pharmaceutical Services is a leading provider of injectable solutions and services that help safely deliver medicines. The Company has over 10,000 team members across 50 sites, including 25 manufacturing facilities, and generated $3.07 billion in net sales in fiscal 2025.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 6.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB